SCHEMBL24095612

SCHEMBL24095612

COc1c(-c2cccnc2C)c2cc(Br)ccc2[nH]c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 5/20 0.43
▸ CCNB2 O95067 3/20 0.43
▸ CDK1 P06493 3/20 0.43
▸ CCNB1 P14635 3/20 0.43
▸ CCNB3 Q8WWL7 3/20 0.43
▸ CDK5 Q00535 2/20 0.43
▸ CDK5R1 Q15078 2/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ PDE2A O00408 1/20 0.41
▸ GSK3A P49840 3/20 0.39
▸ CDK2 P24941 2/20 0.39
▸ CCNE1 P24864 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ PADI4 Q9UM07 2/20 0.39
▸ ERBB2 P04626 1/20 0.39
▸ PTK6 Q13882 1/20 0.39
▸ PTGES O14684 1/20 0.39
▸ ABL1 P00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24095729 0.84 GSK3B (0.46) GSK3BCCNB2CDK1CCNB1CCNB3
SCHEMBL24095578 0.77 MEN1 (0.59) MEN1KMT2ALMNAHPGDPADI4
SCHEMBL24095754 0.74 PDE2A (0.36) PDE2ALMNAPADI4
SCHEMBL24095764 0.70 KDM4E (0.49) GSK3BCCNB2CDK1CCNB1CCNB3
SCHEMBL24095751 0.69 NPC1 (0.42) GSK3BCCNB2CDK1CCNB1CCNB3
SCHEMBL388750 0.69 MEN1 (0.48) MEN1KMT2ALMNAHPGDKDM4E
SCHEMBL24095602 0.67 GSK3B (0.47) GSK3BCCNB2CDK1CCNB1CCNB3
SCHEMBL25849874 0.65 KDM4E (0.60) MEN1KMT2ALMNAHPGDPADI4
SCHEMBL25849925 0.65 MEN1 (0.63) GSK3BMEN1KMT2AGSK3ACDK2
SCHEMBL24095570 0.64 PADI4 (0.53) GSK3BGSK3ACDK2HPGDPADI4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227409-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-07-20 — — US disclosed
US-20230227409-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-07-20 — — US disclosed
WO-2021252681-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227409-A1 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A GSK3B 2486/4885CCNB2 622/4885CDK1 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback